Related Experiment Videos
CD154 (CD40 ligand)
1Cardiovascular Medicine, Department of Medicine, Brigham & Women's Hospital and Harvard Medical School, 221 Longwood Ave, Boston, MA 02115, USA.
Insights
CD40 ligand (CD154) is a key immune mediator involved in T cell-dependent B cell responses. Its dual role in host defense and chronic inflammatory diseases makes CD40/CD154 signaling a promising therapeutic target.
Area of Science:
- Immunology
- Molecular Biology
- Cell Biology
Background:
- CD40 ligand (CD154) was initially identified on activated T lymphocytes.
- It mediates T cell-dependent B cell activation, proliferation, and differentiation.
- CD154 is a member of the tumor necrosis factor (TNF) gene superfamily.
Purpose of the Study:
- To explore the broadened spectrum of CD154 expression and function.
- To elucidate the dual roles of CD154 in immune responses and inflammation.
- To highlight CD40/CD154 interactions as a therapeutic target for inflammatory diseases.
Main Methods:
- The study reviews existing literature on CD154 expression and function.
- It analyzes the mechanisms of CD40/CD154 ligation.
- The research discusses the implications of CD40/CD154 signaling in disease pathogenesis.
Main Results:
- CD154 (CD40 ligand) expression and function extend beyond T lymphocytes.
- CD154 ligation modulates physiological immune processes and triggers pro-inflammatory mediators.
- These mediators are implicated in autoimmune disorders, arthritis, atherosclerosis, and cancer.
Conclusions:
- CD40/CD154 interactions play a central role in immunity and inflammation.
- Targeting CD40/CD154 signaling offers therapeutic potential for chronic inflammatory diseases.
- Both interruption and enhancement of CD40 signaling are being explored for beneficial outcomes.
Abstract:
CD40 ligand, a type II transmembrane protein recently renamed CD154, was originally considered restricted to activated T lymphocytes, functioning as a mediator of T cell-dependent B cell activation, proliferation, and differentiation. However, the spectrum of CD154 expression and function has broadened considerably during recent years, establishing new roles as a central mediator of immunity and inflammation for this member of the tumor necrosis factor (TNF) gene superfamily. The emerging picture indicates that ligation of the receptor CD40 via CD154, most potently in its trimeric form, functions in two ways. CD154 modulates physiologic processes, such as T cell-mediated effector functions and general immune responses required for appropriate host defense, but also triggers the expression of pro-inflammatory mediators, such as cytokines, adhesion molecules, and matrix degrading activities, all of which are associated with the pathogenesis of chronic inflammatory diseases, e.g., autoimmune disorders, arthritis, atherosclerosis, and cancer. Accordingly, CD40/CD154 interactions have advanced as a potential therapeutic target for these diseases, whereby two opposing strategies, interruption as well as enhancement of CD40 signaling, are explored for beneficial outcomes.